Becker's Healthcare December 19, 2024
Alexandra Murphy

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.

The drug is in preclinical stages and aims to target cardiometabolic benefits, including weight reduction, according to a Dec. 18 news release from Merck....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Building Resilience: CDMO Strategies for Drug Supply Chain Stability
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
STAT+: How Trump’s tariffs may raise health care costs, from medical devices to prescription drugs
One Institution’s Evidence-Based Approach to Adopting Biosimilars
Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries

Share This Article